» Articles » PMID: 35302671

Buprenorphine Initiation Strategies for Opioid Use Disorder and Pain Management: A Systematic Review

Overview
Journal Pharmacotherapy
Specialty Pharmacology
Date 2022 Mar 18
PMID 35302671
Authors
Affiliations
Soon will be listed here.
Abstract

Buprenorphine possesses many unique attributes that make it a practical agent for adults and adolescents with opioid use disorder (OUD) and/or acute or chronic pain. Sublingual buprenorphine has been the standard of care for treating OUD, but its use in pain management is not as clearly defined. Current practice guidelines recommend a period of mild-to-moderate withdrawal from opioids before transitioning to buprenorphine due to its ability to displace full agonists from the μ-opioid receptor. However, this strategy can lead to negative physical and psychological outcomes for patients. Novel initiation strategies suggest that concomitant administration of small doses of buprenorphine with opioids can avoid the unwanted withdrawal associated with buprenorphine initiation. We aim to systematically review the buprenorphine initiation strategies that have emerged in the last decade. Embase, PubMed, and Cochrane Databases were searched for relevant literature. Studies were included if they were published in the English language and described the transition to buprenorphine from opioids. Data were collected from each study and synthesized using descriptive statistics. This review included 7 observational studies, 1 feasibility study, and 39 case reports/series which included 924 patients. The strategies utilized between the literature included traditional initiation (47.9%), microdosing with various buprenorphine formulations (16%), and miscellaneous methods (36.1%). Traditional initiation and microdosing initiation were compared in the data synthesis and analysis; miscellaneous methods were omitted given the high variability between methods. Overall, 95.6% of patients in the traditional initiation group and 96% of patients in the microdosing group successfully rotated to sublingual buprenorphine. Initiation regimens can vary widely depending on patient-specific factors and buprenorphine formulation. A variety of buprenorphine transition strategies are published in the literature, many of which were effective for patients with OUD, pain, or both.

Citing Articles

Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings.

Nicholas C, Horton D, Malicki J, Baltes A, Hutson P, Brown R Psychedelic Med (New Rochelle). 2025; 1(4):253-261.

PMID: 40046866 PMC: 11661506. DOI: 10.1089/psymed.2023.0012.


Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: an updated systematic review.

Adams K, Waters K, Sobieraj D Addict Sci Clin Pract. 2025; 20(1):19.

PMID: 39980050 PMC: 11841166. DOI: 10.1186/s13722-025-00548-z.


Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits.

Davis M Drugs. 2025; 85(2):215-230.

PMID: 39873915 DOI: 10.1007/s40265-024-02128-y.


Age and racial and ethnic disparities in filled buprenorphine prescriptions post-emergency department visit in Nevada.

Ajumobi O, Friedman S, Westhoff J, Granner M, Lucero J, Koch B J Am Coll Emerg Physicians Open. 2024; 5(5):e13272.

PMID: 39247155 PMC: 11377888. DOI: 10.1002/emp2.13272.


Emergency department management of opioid use disorder in pediatric patients.

Schwarz E, Dietrich A, Sandelich S, Hooley G, Rose E, Ruttan T J Am Coll Emerg Physicians Open. 2024; 5(5):e13265.

PMID: 39193084 PMC: 11345534. DOI: 10.1002/emp2.13265.


References
1.
Irwin M, Petersen K, Smith M . Rapid Buprenorphine Induction for Cancer Pain in Pregnancy. J Palliat Med. 2020; 24(8):1257-1262. DOI: 10.1089/jpm.2020.0524. View

2.
Sandhu R, Zivanovic R, Klaire S, Nikoo M, Rozylo J, Azar P . Buprenorphine/naloxone induction for treatment of acute on chronic pain using a micro-dosing regimen: A case report. Can J Pain. 2022; 3(1):79-84. PMC: 8730552. DOI: 10.1080/24740527.2019.1599279. View

3.
Mortaji P, Terasaki D, Moo-Young J . Advanced Inpatient Management of Opioid Use Disorder in a Patient Requiring Serial Surgeries. J Gen Intern Med. 2021; 36(8):2448-2451. PMC: 8342648. DOI: 10.1007/s11606-021-06739-z. View

4.
Ward H, Barnett B, Suzuki J . Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report. Subst Abus. 2019; 40(2):140-145. PMC: 7641008. DOI: 10.1080/08897077.2019.1573776. View

5.
Vogel M, Kock P, Strasser J, Wiesbeck G, Walter M, Dursteler K . Chronic High-Dose Buprenorphine Does Not Block Subjective High from Diacetylmorphine in a Patient in Heroin-Assisted Treatment. J Psychoactive Drugs. 2019; 51(4):377-382. DOI: 10.1080/02791072.2019.1610200. View